Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MOR

Morphosys AG ADR

May 14 • 04:00PM ET

18.39

Dollar change +0.32
Percentage change 1.77	%

Healthcare • Biotechnology • Germany • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.48	Insider Own	0.30%	Shs Outstand	150.41M	Perf Week	2.51%
Market Cap	2.77B	Forward P/E	-	EPS next Y	-0.89	Insider Trans	0.00%	Shs Float	150.21M	Perf Month	2.05%
Income	-500.55M	PEG	-	EPS next Q	-0.54	Inst Own	16.65%	Short Float	0.83%	Perf Quarter	7.04%
Sales	220.60M	P/S	12.56	EPS this Y	0.68%	Inst Trans	5.72%	Short Ratio	2.35	Perf Half Y	141.97%
Book/sh	-1.88	P/B	-	EPS next Y	40.50%	ROA	-22.56%	Short Interest	1.25M	Perf Year	222.63%
Cash/sh	4.52	P/C	4.07	EPS next 5Y	-	ROE	-185.77%	52W Range	4.18 - 18.31	Perf YTD	85.76%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-23.10%	ROI	-	52W High	0.46%	Beta	1.18
Dividend TTM	-	Quick Ratio	1.38	Sales past 5Y	67.37%	Gross Margin	75.93%	52W Low	339.43%	ATR (14)	0.23
Dividend Ex-Date	-	Current Ratio	1.38	EPS Y/Y TTM	-453.93%	Oper. Margin	-219.08%	RSI (14)	65.34	Volatility	0.96% 1.15%
Employees	564	Debt/Eq	-	Sales Y/Y TTM	-28.78%	Profit Margin	-226.90%	Recom	3.00	Target Price	18.24
Option/Short	Yes / No	LT Debt/Eq	-	EPS Q/Q	-551.32%	Payout	-	Rel Volume	0.55	Prev Close	18.07
Sales Surprise	-49.94%	EPS Surprise	-638.62%	Sales Q/Q	-55.30%	Earnings	Apr 29 AMC	Avg Volume	530.49K	Price	18.39
SMA20	2.71%	SMA50	2.29%	SMA200	62.37%	Trades		Volume	293,920	Change	1.77%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-14-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Jan-16-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$9.20 → $10.40
Oct-13-23	Upgrade	Morgan Stanley	Underweight → Overweight	$3.70 → $9.20
Sep-15-23	Upgrade	Goldman	Sell → Neutral	$3.50 → $9.25
Jul-17-23	Upgrade	Deutsche Bank	Sell → Hold
Jun-16-23	Upgrade	JP Morgan	Underweight → Overweight	$3.30 → $10
Jun-16-23	Initiated	Wells Fargo	Overweight	$17
May-31-23	Initiated	UBS	Buy
Jan-06-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Dec-16-22	Downgrade	Goldman	Neutral → Sell
Nov-15-22	Downgrade	Stifel	Buy → Hold
Nov-15-22	Downgrade	Citigroup	Neutral → Sell
Oct-24-22	Downgrade	Deutsche Bank	Hold → Sell	$196 → $150
Jan-14-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$22 → $14
Sep-13-21	Resumed	Goldman	Neutral	$12
Aug-06-21	Downgrade	Deutsche Bank	Buy → Hold
Jun-11-21	Downgrade	JP Morgan	Overweight → Neutral	$24
Jun-03-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Jun-03-21	Downgrade	Bryan Garnier	Buy → Neutral
May-24-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight

Show Previous Ratings

May-09-24 10:46AM	Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2024 Earnings Call Transcript (Insider Monkey)
Apr-30-24 07:52AM	MOR Stock Earnings: MorphoSys Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
Apr-29-24 04:01PM	MorphoSys AG Reports First Quarter 2024 Financial Results (Business Wire)
Apr-24-24 11:00AM	MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting (ACCESSWIRE)
Apr-23-24 10:12AM	Incyte, fresh off gaining MorphoSys drug, buys Escient for $750M (FierceBiotech.com)
06:26AM	Loading…
Apr-12-24 06:26AM	Novartis may have bought MorphoSys, but it really only had eyes for BET inhibitor pelabresib: filing (FierceBiotech.com)
Apr-11-24 09:00AM	MorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis (ACCESSWIRE)
Apr-03-24 08:48AM	Genmab Buys ProfoundBio for $1.8B to Boost Oncology Portfolio (Investopedia)
Mar-30-24 03:52PM	11 Oversold Blue Chip Stocks to Buy Right Now (Insider Monkey)
Mar-22-24 02:50AM	MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act (ACCESSWIRE)
Mar-15-24 10:37AM	MorphoSys AG (NASDAQ:MOR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-13-24 04:02PM	MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (Business Wire)
Mar-11-24 12:44PM	20 Highest Paying Countries for Biotechnology (Insider Monkey)
Mar-07-24 04:15PM	Invitation to MorphoSys' Full Year Results 2023 Conference Call on March 14, 2024 (ACCESSWIRE)
Mar-05-24 02:56AM	13 Best Pharma Dividend Stocks To Buy in 2024 (Insider Monkey)
12:00PM	Loading…
Mar-04-24 12:00PM	MorphoSys AG Unsponsored ADR (MOR) is a Great Momentum Stock: Should You Buy? (Zacks)
Feb-16-24 03:55AM	5 Top Performing European Stocks So Far in 2024 (Insider Monkey)
Feb-15-24 12:00PM	What Makes MorphoSys AG Unsponsored ADR (MOR) a Strong Momentum Stock: Buy Now? (Zacks)
Feb-06-24 10:29AM	Novartis to acquire German Biotech MorphoSys for $2.9B, Expanding Cancer Drug Pipeline (Investopedia) -5.79%
Feb-05-24 05:44PM	Novartis acquiring cancer drug developer Morphosys for 2.7 billion (CNBC TV) +56.01%
05:30PM	Novartis to Buy MorphoSys for $2.9 Billion; Deal Seen Closing in 1H (The Wall Street Journal)
05:15PM	MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for EUR 2.7 Billion Equity Value (ACCESSWIRE)
05:15PM	MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for 2.7 Billion Equity Value (ACCESSWIRE)
04:46PM	Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi) (Business Wire)
04:45PM	Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash (GlobeNewswire)
02:39PM	Why Is MorphoSys (MOR) Stock Up 50% Today? (InvestorPlace)
Jan-30-24 03:15AM	MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability (ACCESSWIRE)
Jan-08-24 02:20AM	MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference (ACCESSWIRE)
Dec-10-23 07:31PM	MorphoSys Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study (Business Wire)
Nov-21-23 09:09AM	Why Is MorphoSys (MOR) Stock Down 20% Today? (InvestorPlace) -22.35%
05:53AM	Loading…
05:53AM	MorphoSys, after saying AbbVie 'failed', defends own mixed blood cancer data, plots approval filings (FierceBiotech.com)
Nov-20-23 04:50PM	Ad hoc: MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction (ACCESSWIRE)
04:30PM	MorphoSys Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction (Business Wire)
Nov-17-23 09:59AM	MorphoSys AG (NASDAQ:MOR) Q3 2023 Earnings Call Transcript (Insider Monkey) -5.81%
Nov-15-23 04:01PM	MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results (Business Wire) -7.09%
Nov-09-23 04:20PM	Invitation to MorphoSys' Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023 (ACCESSWIRE) -5.08%
Nov-02-23 09:45AM	MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting (ACCESSWIRE) -7.39%
Oct-25-23 05:10AM	MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023 (ACCESSWIRE)
Sep-15-23 09:32AM	Shake Shack upgraded, DoorDash downgraded: Wall Street's top analyst calls (The Fly)
Sep-12-23 04:20PM	MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer (ACCESSWIRE)
Aug-09-23 04:01PM	MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results (Business Wire)
Jun-26-23 04:00PM	Wells Fargo Predicts up to 125% Rally for These 2 Stocks Heres Why They Have Solid Upside (TipRanks)
May-03-23 04:01PM	MorphoSys AG Reports First Quarter 2023 Financial Results (Business Wire)
Apr-27-23 04:20PM	Invitation to MorphoSys First Quarter 2023 Financial Results Conference Call on May 4, 2023 (ACCESSWIRE)
Apr-17-23 03:32AM	MorphoSys AG (ETR:MOR) Stock Catapults 36% Though Its Price And Business Still Lag The Industry (Simply Wall St.)
Apr-16-23 03:01PM	MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix) (Business Wire)
Mar-19-23 11:15PM	MorphoSys AG (NASDAQ:MOR) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-15-23 04:03PM	MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (Business Wire) -5.79%
Mar-09-23 04:20PM	Invitation to MorphoSys' Full Year Results 2022 Conference Call on March 16, 2023 (ACCESSWIRE)
Mar-02-23 04:00AM	MorphoSys Stops Work and Operations on Pre-Clinical Research Programs (ACCESSWIRE)
04:00AM	Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters (ACCESSWIRE)
Jan-09-23 01:20AM	MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024 (ACCESSWIRE)
Jan-05-23 06:00AM	MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability (ACCESSWIRE) -6.01%
Dec-07-22 09:48AM	MorphoSys Inks Licensing Agreement With Novartis For Preclinical Cancer Programs (Benzinga)
Nov-28-22 04:30PM	MorphoSys AG: Financial Calendar 2023 (ACCESSWIRE)
Nov-19-22 01:45AM	Earnings Release: Here's Why Analysts Cut Their MorphoSys AG (ETR:MOR) Price Target To 29.30 (Simply Wall St.)
Nov-16-22 04:01PM	MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results (Business Wire)
Nov-14-22 04:11PM	Roche's Alzheimer's Drug Fails In Phase 3; Here's The Fallout For Biogen, Lilly, Prothena And Others (Investor's Business Daily) -27.84%
07:23AM	Roche's Another Alzheimer's Hopeful Flops In Phase 3 Program, Second Trial Setback Within Months (Benzinga)
06:41AM	Biogen shares jump 4.7% premarket on hopes for its Alzheimer's treatment lecanemab (MarketWatch)
05:22AM	MorphoSys shares plunge after partner Roche says Alzheimer's drug trials didn't meet goals (MarketWatch)
01:30AM	MorphoSys Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimers Disease (ACCESSWIRE)
Nov-10-22 04:30PM	Invitation to MorphoSys Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022 (ACCESSWIRE) +7.89%
Nov-08-22 12:45AM	MorphoSys AG (ETR:MOR) most popular amongst individual investors who own 51% of the shares, institutions hold 45% (Simply Wall St.)
Nov-03-22 09:25AM	MorphoSys to Share New Data on Pelabresib and Monjuvi(R) (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting (ACCESSWIRE)
Oct-28-22 11:14AM	MorphoSys Highlights Preliminary Data From Tulmimetostat Study Across Broad Array of Advanced Tumors (Benzinga) -5.70%
Oct-27-22 04:20PM	MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors (ACCESSWIRE)
03:10AM	GSK, MorphoSys' Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis (ACCESSWIRE)
Oct-21-22 06:00AM	MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022 (ACCESSWIRE)
Sep-29-22 09:21AM	MorphoSys' Monjuvi Shows Long-Term Durable Response In Blood Cancer Settings (Benzinga)
Aug-06-22 02:00PM	MorphoSys AG (MOR) Q2 2022 Earnings Call Transcript (Motley Fool)
Aug-03-22 04:01PM	MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results (Business Wire) +5.45%
Jul-28-22 04:20PM	MorphoSys AG: Invitation to MorphoSys' Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022 (ACCESSWIRE) -8.31%
Jul-26-22 05:40AM	MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022 (ACCESSWIRE) +5.13%
05:30AM	MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022 (ACCESSWIRE)
Jun-15-22 08:30AM	I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210 (PR Newswire)
Jun-14-22 04:57PM	MorphoSys Stock Skyrockets On Entering Equity Participation and License Agreements With HIBio (Benzinga)
04:01PM	MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210 (Business Wire)
11:00AM	MorphoSys (MOR) Gains on Oncology Collaboration With Pfizer (Zacks)
Jun-10-22 03:15AM	MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022 (Business Wire) -7.89%
May-18-22 08:05PM	MorphoSys AG Reports Outcome of Annual General Meeting 2022 (ACCESSWIRE)
May-12-22 10:45AM	MorphoSys to Present New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) at the 2022 European Hematology Association (EHA) and American Society of Clinical Oncology (ASCO) Annual Meetings (Business Wire)
May-05-22 08:30PM	MorphoSys AG (MOR) Q1 2022 Earnings Call Transcript (Motley Fool)
May-04-22 04:01PM	MorphoSys AG Reports First Quarter 2022 Financial Results (Business Wire)
Apr-28-22 04:45PM	Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call on May 5, 2022 (ACCESSWIRE)
Apr-12-22 09:55AM	Wall Street Analysts Believe MorphoSys AG Unsponsored ADR (MOR) Could Rally 213%: Here's is How to Trade (Zacks)
Mar-23-22 07:05AM	MorphoSys-Incyte Partnered Minjuvi Temporarily Approved In Switzerland (Benzinga)
Mar-22-22 04:45PM	MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL (ACCESSWIRE) -9.54%
Mar-16-22 04:07PM	MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update (Business Wire) +6.01%
Mar-15-22 04:40PM	National Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Preferred Regimen in Its Clinical Practice Guidelines in Oncology for B-cell Lymphomas (ACCESSWIRE)
Mar-10-22 04:35PM	Invitation to MorphoSys' Full Year Results 2021 Conference Call on March 17, 2022 (ACCESSWIRE)
02:50PM	MorphoSys Discontinues US Discovery Activities, Takes 231M Impairment Charge (Benzinga)
11:30AM	MorphoSys AG Reports Non-Cash Impairment Charge of 231 Million on Goodwill After Consolidation of Research and Discovery Functions; Corresponding Increase of Group Operating Expenses in 2021 (ACCESSWIRE)
Jan-24-22 04:20PM	MorphoSys ranked Number One in Germany for Female Representation at Leadership Level in European Women on Boards' Gender Equality Index Report (ACCESSWIRE) -5.57%
Jan-18-22 01:00AM	MorphoSys Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance (ACCESSWIRE)
Jan-10-22 02:20AM	MorphoSys To Present At the 40th Annual J.P. Morgan Healthcare Conference (ACCESSWIRE) +5.90%
Dec-12-21 09:00AM	MorphoSys Presents Latest Data from the Phase 2 MANIFEST Study Evaluating the Potential of Pelabresib in the Treatment of Myelofibrosis (ACCESSWIRE)
Dec-11-21 12:00PM	MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (Business Wire)
12:00PM	MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (ACCESSWIRE)
Nov-29-21 04:15PM	Corporate Calendar 2022 (ACCESSWIRE)

MorphoSys AG is a biopharmaceutical company, which engages in the development and commercialization of cancer therapeutics. Its clinical programs focus on Pelabresib and Tulmimetostat. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MOR

Morphosys AG ADR

Upgrade your FINVIZ experience